Related references
Note: Only part of the references are listed.IMbrave150: Updated overall survival (OS) data from a global, randomized, open-label phase III study of atezolizumab (atezo) plus bevacizumab (bev) versus sorafenib (sor) in patients (pts) with unresectable hepatocellular carcinoma (HCC).
Richard S. Finn et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Durvalumab: an investigational anti-PD-L1 antibody for the treatment of biliary tract cancer
Alessandro Rizzo et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2021)
Immune-based combinations for advanced hepatocellular carcinoma: shaping the direction of first-line therapy
Alessandro Rizzo et al.
FUTURE ONCOLOGY (2021)
Safety and efficacy of pembrolizumab plus lenvatinib versus pembrolizumab and lenvatinib monotherapies in cancers: A systematic review
Dun-Chang Mo et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2021)
NASH limits anti-tumour surveillance in immunotherapy-treated HCC
Dominik Pfister et al.
NATURE (2021)
Atezolizumab in advanced hepatocellular carcinoma: good things come to those who wait
Alessandro Rizzo et al.
IMMUNOTHERAPY (2021)
NASH limits anti-tumour surveillance in immunotherapy-treated HCC
Dominik Pfister et al.
NATURE (2021)
The role of vascular endothelial growth factor in the hypoxic and immunosuppressive tumor microenvironment: perspectives for therapeutic implications
Ryota Tamura et al.
MEDICAL ONCOLOGY (2020)
Updated efficacy and safety of KEYNOTE-224: A phase II study of pembrolizumab (pembro) in patients with advanced hepatocellular carcinoma (HCC).
Masatoshi Kudo et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial
Richard S. Finn et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Molecular therapies for HCC: Looking outside the box
Sandrine Faivre et al.
JOURNAL OF HEPATOLOGY (2020)
Challenges of combination therapy with immune checkpoint inhibitors for hepatocellular carcinoma
Ann-Lii Cheng et al.
JOURNAL OF HEPATOLOGY (2020)
Efficacy of Cabozantinib and Nivolumab in Treating Hepatocellular Carcinoma with RET Amplification, High Tumor Mutational Burden, and PD-L1 Expression
Xiaobo Yang et al.
ONCOLOGIST (2020)
Resistance to Checkpoint Inhibition in Cancer Immunotherapy
Luisa Barrueto et al.
TRANSLATIONAL ONCOLOGY (2020)
Nivolumab for the treatment of hepatocellular carcinoma
Lim Chiew Woon et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2020)
Efficacy, tolerability, and biologic activity of a novel regimen of tremelimumab (T) in combination with durvalumab (D) for patients (pts) with advanced hepatocellular carcinoma (aHCC).
Robin Kate Kelley et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma
Richard S. Finn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Immune-based therapies for hepatocellular carcinoma
David J. Pinato et al.
ONCOGENE (2020)
Cabozantinib for the Treatment of Advanced Hepatocellular Carcinoma: Current Data and Future Perspectives
Joerg Trojan
DRUGS (2020)
Adjuvant systemic treatment in hepatocellular carcinoma: tempted to do something, rather than nothing
Alessandro Rizzo et al.
FUTURE ONCOLOGY (2020)
Bevacizumab (Avastin®) in cancer treatment: A review of 15 years of clinical experience and future outlook
Josep Garcia et al.
CANCER TREATMENT REVIEWS (2020)
Immuno-Oncotherapeutic Approaches in Advanced Hepatocellular Carcinoma
Robin Park et al.
VACCINES (2020)
Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: Current Status and Novel Perspectives
Piera Federico et al.
CANCERS (2020)
Immune Checkpoint Inhibitors for Unresectable Hepatocellular Carcinoma
Mohamed A. Abd El Aziz et al.
VACCINES (2020)
Combination Antiangiogenic and Immunotherapy for Advanced Hepatocellular Carcinoma: Evidence to Date
Alison L. Raybould et al.
JOURNAL OF HEPATOCELLULAR CARCINOMA (2020)
Beyond EGFR, ALK and ROS1: Current evidence and future perspectives on newly targetable oncogenic drivers in lung adenocarcinoma
Giuseppe Lamberti et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2020)
Systematic Review and Network Meta-Analysis of Immune Checkpoint Inhibitors in Combination with Chemotherapy as a First-Line Therapy for Extensive-Stage Small Cell Carcinoma
Hsiao-Ling Chen et al.
CANCERS (2020)
Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial
Laurence Albiges et al.
ESMO OPEN (2020)
Systemic Treatment for Advanced Hepatocellular Carcinoma
Mohamed Bouattour et al.
LIVER CANCER (2019)
Immunotherapy in hepatocellular carcinoma
Luigi Buonaguro et al.
ANNALS OF HEPATOLOGY (2019)
The Intersection between Tumor Angiogenesis and Immune Suppression
Osama E. Rahma et al.
CLINICAL CANCER RESEARCH (2019)
First-line avelumab plus axitinib in patients with advanced hepatocellular carcinoma: Results from a phase 1b trial (VEGF Liver 100).
Masatoshi Kudo et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Building on the anti-PD1/PD-L1 backbone: combination immunotherapy for cancer
Alvaro H. Ingles Garces et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2019)
Combination of CTLA-4 and PD-1 blockers for treatment of cancer
Anand Rotte
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2019)
Immunotherapy for hepatocellular carcinoma: Current and future
Michael P. Johnston et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2019)
LBA38_PRCheckMate 459: A randomized, multi-center phase III study of nivolumab (NIVO) vs sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma (aHCC)
T Yau et al.
ANNALS OF ONCOLOGY (2019)
Hepatocellular carcinoma: an update on investigational drugs in phase I and II clinical trials
Anne Noonan et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2019)
EGFR-TKI resistance promotes immune escape in lung cancer via increased PD-L1 expression
Shunli Peng et al.
MOLECULAR CANCER (2019)
Combination anti-CTLA-4 plus anti-PD-1 checkpoint blockade utilizes cellular mechanisms partially distinct from monotherapies
Spencer C. Wei et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2019)
Predictive Factors for Response to PD-1/PD-L1 Checkpoint Inhibition in the Field of Hepatocellular Carcinoma: Current Status and Challenges
Zuzana Macek Jilkova et al.
CANCERS (2019)
Cabozantinib in Combination with Immunotherapy for Advanced Renal Cell Carcinoma and Urothelial Carcinoma: Rationale and Clinical Evidence
Paulo Bergerot et al.
MOLECULAR CANCER THERAPEUTICS (2019)
Lenvatinib for the treatment of unresectable hepatocellular carcinoma: evidence to date
Nicola Personeni et al.
JOURNAL OF HEPATOCELLULAR CARCINOMA (2019)
Lenvatinib for the treatment of renal cell carcinoma
Giandomenico Roviello et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2018)
Pembrolizumab as first-line therapy for metastatic non-small-cell lung cancer
Martin Reck
IMMUNOTHERAPY (2018)
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
Andrew X. Zhu et al.
LANCET ONCOLOGY (2018)
Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma
David F. McDermott et al.
NATURE MEDICINE (2018)
Mouse models of hepatocellular carcinoma: an overview and highlights for immunotherapy research
Zachary J. Brown et al.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2018)
Metronomic capecitabine vs. best supportive care in Child-Pugh B hepatocellular carcinoma: a proof of concept
Stefania De Lorenzo et al.
SCIENTIFIC REPORTS (2018)
Combinations of Bevacizumab With Cancer Immunotherapy
Daniel S. Chen et al.
CANCER JOURNAL (2018)
Molecular therapies and precision medicine for hepatocellular carcinoma
Josep M. Llovet et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2018)
LBA26Updated safety and clinical activity results from a phase Ib study of atezolizumab + bevacizumab in hepatocellular carcinoma (HCC)
M J Pishvaian et al.
ANNALS OF ONCOLOGY (2018)
Nivolumab for the treatment of hepatocellular carcinoma
Fabian Finkelmeier et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2018)
Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial
Anthony B. El-Khoueiry et al.
LANCET (2017)
PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism, Combinations, and Clinical Outcome
Hashem O. Alsaab et al.
FRONTIERS IN PHARMACOLOGY (2017)
Anti-angiogenesis for cancer revisited: Is there a role for combinations with immunotherapy?
Rakesh R. Ramjiawan et al.
ANGIOGENESIS (2017)
CTLA-4 and PD-1 Pathways Similarities, Differences, and Implications of Their Inhibition
Elizabeth I. Buchbinder et al.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS (2016)
Rationally combining anti-VEGF therapy with checkpoint inhibitors in hepatocellular carcinoma
Tai Hato et al.
IMMUNOTHERAPY (2016)
Novel drugs in clinical development for hepatocellular carcinoma
Oliver Waidmann et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2015)
Cancer immunotherapy: harnessing the immune system to battle cancer
Yiping Yang
JOURNAL OF CLINICAL INVESTIGATION (2015)
The blockade of immune checkpoints in cancer immunotherapy
Drew M. Pardoll
NATURE REVIEWS CANCER (2012)
Share Paper
